{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-020512","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2021-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.277663+00:00","generated_at":"2026-06-29T09:21:36.099019+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K","bullets":["Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.","Loan bears 8% interest, due in 12 months; convertible into Series D-1 Preferred at $2.862/share (each converts to 10 common shares).","On Aug 16, 2021, CFO Heather Raines invested $200,000 via a 2021 Note under the same terms.","Proceeds to fund drug discovery/development and general administrative expenses.","Issuance exempt from registration under Section 4(a)(2) or Rule 506 of the Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-020512","json":"https://secwatch.observer/filing/0001493152-21-020512.json","markdown":"https://secwatch.observer/filing/0001493152-21-020512.md","text":"https://secwatch.observer/filing/0001493152-21-020512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/0001493152-21-020512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:21:36.099019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}